Eight brokerages currently cover CVRx, assigning an average recommendation of “Moderate Buy.” Two firms rate the company with a sell opinion, five with a buy opinion and one with a strong buy—reflecting a broadly positive outlook. Over the past year, analysts’ twelve-month target prices have averaged $13.17, suggesting potential upside from current levels.

On November 6th, Cantor Fitzgerald raised its price objective from $11.00 to $13.00 and maintained an overweight rating. That same day, Canaccord Genuity Group lifted its target from $9.00 to $11.00 and issued a buy rating. In late December, Weiss Ratings reiterated a sell (d–) rating, underscoring continuing divergence among analysts.

In the quarter ending November 5th, CVRx reported revenue of $14.69 million, exceeding the consensus estimate of $14.16 million. The company posted a loss per share of $0.49, narrowly beating the estimate of a $0.50 loss. Despite generating growth in top-line revenue, CVRx recorded a negative net margin near 93% and a return on equity of minus 84.5%.

A major shareholder sold 52,332 shares in early November, realizing proceeds of approximately $534,310 and reducing their stake by 1.28%. Over the past three months, insiders have divested 56,232 shares, representing 13.9% ownership by that group. Meanwhile, leading institutions such as Vanguard Group, Balyasny Asset Management and Marshall Wace have all increased their holdings, with combined institutional ownership now standing at 75.3%.